Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice.
The inhibitor of apoptosis proteins (IAPs) are a family of antiapoptotic proteins that bind and inhibit caspases 3, 7, and/or 9, but not caspase 8. Growing evidence also indicates that IAPs also modulate cell division, cell cycle progression, and signal transduction pathways. As our basic understanding of IAPs has increased, the knowledge is being translated into clinically useful applications in the diagnosis and treatment of malignancy. For example, IAPs such as survivin are being investigated as diagnostic markers for the presence of occult malignancy. In addition, IAP overexpression is a poor prognostic marker in a variety of solid tumors and hematologic malignancies. Finally, IAPs are attractive therapeutic targets, and efforts are under way to develop antisense and chemical IAP inhibitors that may be useful for the treatment of a variety of malignancies. For all of these potential clinical applications, however, the challenge remains to incorporate these findings into actual clinical practice.
Schimmer
Aaron D
AD
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada. aaron.schimmer@utoronto.ca
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism; D004789:Enzyme Activation; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D007527:Isoenzymes; D011506:Proteins / Q000502:physiology*
D061945:Caspase Inhibitors; D051034:Inhibitor of Apoptosis Proteins; D007527:Isoenzymes; D011506:Proteins; D020169:Caspases